Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 116-125

  Tang, Ying Zi ^a   Liu, Lin ^a   Pan, Mei Min ^a   Wang, Yu Ming ^a   Deng, Guo Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Full genome; Hepatitis B virus; Mutations

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; EPITOPE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES DIVERSITY; VIRUS GENE; VIRUS GENOME;

ADULT; ANTIVIRAL AGENTS; EVOLUTION, MOLECULAR; FEMALE; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; NUCLEOTIDES; PHYLOGENY;

HEPATITIS B VIRUS;

EID: 79953846015     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.03.183     Document Type: Article

References (39)

1. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
2. Blanchet M., Sureau C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J. Virol. 2007, 81:5841-5849.
3. Bruss V., Thomssen R. Mapping a region of the large envelope protein required for hepatitis B virion maturation. J. Virol. 1994, 68:1643-1650.
4. Chen C.H., Changchien C.S., Lee C.M., Hung C.H., Hu T.H., Wang J.H., Wang J.C., Lu S.N. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J. Infect. Dis. 2008, 198:1634-1642.
5. Chen C.H., Lee C.M., Tung W.C., Wang J.H., Hung C.H., Hu T.H., Wang J.C., Lu S.N., Changchien C.S. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J. Hepatol. 2010, 52:478-485.
6. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
7. Chuang W.L., Omata M., Ehata T., Yokosuka O., Ito Y., Imazeki F., Lu S.N., Chang W.Y., Ohto M. Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology 1993, 104:263-271.
8. Domingo E., Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res. 2007, 127:131-150.
9. Drummond A., Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 2007, 7:214.
10. Ehata T., Omata M., Chuang W.L., Yokosuka O., Ito Y., Hosoda K., Ohto M. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J. Clin. Invest. 1993, 91:1206-1213.
11. Enomoto M., Tamori A., Kohmoto M.T., Morikawa H., Habu D., Sakaguchi H., Takeda T., Seki S., Kawada N., Shiomi S., Nishiguchi S. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J. Med. Virol. 2007, 79:1664-1670.
12. Feng B., Wei L., Chen M., Wang L. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B. Microbiol. Res. 2008, 163:487-492.
13. Ferrari C., Penna A., Bertoletti A., Valli A., Antoni A.D., Giuberti T., Cavalli A., Petit M.A., Fiaccadori F. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 1990, 145:3442-3449.
14. Ferrari C., Cavalli A., Penna A., Valli A., Bertoletti A., Pedretti G., Pilli M., Vitali P., Neri T.M., Giuberti T. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 1992, 103:255-263.
15. Guo J.J., Li Q.L., Shi X.F., Zhang D.Z., Zeng A.Z., Feng T., Huang A.L. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res. 2009, 81:180-183.
16. Hong H.J., Ryu C.J., Hur H., Kim S., Oh H.K., Oh M.S., Park S.Y. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004, 318:134-141.
17. Horiike N., Duong T.N., Michitaka K., Joko K., Hiasa Y., Konishi I., Yano M., Onji M. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences. J. Med. Virol. 2007, 79:911-918.
18. Ji F., Zhou L., Ma S., Li F., Ding H., Zeng C. Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient. J. Med. Virol. 2009, 81:1551-1559.
19. Kim H., Jee Y.M., Song B.C., Hyun J.W., Mun H.S., Kim H.J., Oh E.J., Yoon J.H., Kim Y.J., Lee H.S., Hwang E.S., Cha C.Y., Kook Y.H., Kim B.J. Analysis of hepatitis B virus quasispecies distribution in a Korean chronic patient based on the full genome sequences. J. Med. Virol. 2007, 79:212-219.
20. Kuroki K., Floreani M., Mimms L.T., Ganem D. Epitope mapping of the PreS1 domain of the hepatitis B virus large surface protein. Virology 1990, 176:620-624.
21. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
22. Librado P., Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics 2009, 25:1451-1452.
23. Liu C.J., Chen P.J., Lai M.Y., Kao J.H., Chang C.F., Wu H.L., Shau W.Y., Chen D.S. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003, 124:80-90.
24. Lole K.S., Bollinger R.C., Paranjape R.S., Gadkari D., Kulkarni S.S., Novak N.G., Ingersoll R., Sheppard H.W., Ray S.C. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 1999, 73:152-160.
25. Maeng C.Y., Ryu C.J., Gripon P., Guguen-Guillouzo C., Hong H.J. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology 2000, 270:9-16.
26. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 1996, 93:4398-4402.
27. Pallier C., Castera L., Soulier A., Hezode C., Nordmann P., Dhumeaux D., Pawlotsky J.M. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 2006, 80:643-653.
28. Park J.H., Cho E.W., Lee Y.J., Shin S.Y., Kim K.L. Determination of the protective effects of neutralizing anti-hepatitis B virus (HBV) immunoglobulins by epitope mapping with recombinant HBV surface-antigen proteins. Microbiol. Immunol. 2000, 44:703-710.
29. Pawlotsky J.M. The concept of hepatitis B virus mutant escape. J. Clin. Virol. 2005, 34(Suppl. 1):S125-S129.
30. Salfeld J., Pfaff E., Noah M., Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 1989, 63:798-808.
31. Tai P.C., Banik D., Lin G.I., Pai S., Pai K., Lin M.H., Yuoh G., Che S., Hsu S.H., Chen T.C., Kuo T.T., Lee C.S., Yang C.S., Shih C. Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J. Virol. 1997, 71:4852-4856.
32. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 2007, 24:1596-1599.
33. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., Higgins D.G. The CLUSTAL_X windows interface. flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997, 25:4876-4882.
34. Torresi J., Earnest-Silveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., Fyfe J., Sozzi T., Jackson D.C. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002, 293:305-313.
35. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., Hwang L.H., Chang T.H., Chen D.S. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J. Clin. Invest. 1992, 89:87-96.
36. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., Gibbs C.S., Parvaz P., Werle B., Trepo C., Zoulim F. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 2003, 39:1085-1089.
37. Villet S., Ollivet A., Pichoud C., Barraud L., Villeneuve J.P., Trépo C., Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007, 46:531-538.
38. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44:703-712.
39. Zhou Y., Holmes E.C. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J. Mol. Evol. 2007, 65:197-205.